Characterizing a Clinical Trial – Representative, Real-World Population with Heart Failure with Reduced Ejection Fraction

References

• Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139–e596. doi:10.1161/CIR.0000000000000757
   PubMed Web of Science ®Google Scholar
• Shah KS, Xu H, Matsouaka RA, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017;70(20):2476–2486. doi:10.1016/j.jacc.2017.08.074
   PubMed Web of Science ®Google Scholar
• Malik FI, Hartman JJ, Elias KA, et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science. 2011;331(6023):1439–1443. doi:10.1126/science.1200113
   PubMed Web of Science ®Google Scholar
• Kish T. New heart failure medications aim to fill significant gaps in treatment. P T. 2017;42(12):764–766.
   Google Scholar
• Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet. 2005;365(9453):82–93. doi:10.1016/S0140-6736(04)17670-8
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Diaz R, Felker GM, et al. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. Eur J Heart Fail. 2020;22(11):2160–2171.
   Web of Science ®Google Scholar
• Kaplinsky E, Mallarkey G. Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil. Drugs Context. 2018;7:212518. doi:10.7573/dic.212518
   Google Scholar
• Bielinski SJ, Pathak J, Carrell DS, et al. A robust e-Epidemiology Tool in phenotyping heart failure with differentiation for preserved and reduced ejection fraction: the Electronic Medical Records and Genomics (eMERGE) network. J Cardiovasc Transl Res. 2015;8(8):475–483. doi:10.1007/s12265-015-9644-2
   Web of Science ®Google Scholar
• Xu H, Stenner SP, Doan S, Johnson KB, Waitman LR, Denny JC MedEx: a medication information extraction system for clinical narratives. J Am Med Inform Assoc. 2010;17(1):19–24.
   Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. doi:10.1056/NEJMoa1409077
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. doi:10.1056/NEJMoa1911303
   PubMed Web of Science ®Google Scholar
• Mentz RJ, Xu H, O’Brien EC, et al. PROVIDE-HF primary results: patient-reported outcomes investigation following initiation of drug therapy with Entresto (sacubitril/valsartan) in heart failure. Am Heart J. 2020;230:35–43. doi:10.1016/j.ahj.2020.09.012
   Web of Science ®Google Scholar
• Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883–1893. doi:10.1056/NEJMoa1915928
   PubMed Web of Science ®Google Scholar
• Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106(17):2194–2199. doi:10.1161/01.CIR.0000035653.72855.BF
   PubMed Web of Science ®Google Scholar
• CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429–1435. doi:10.1056/NEJM198706043162301
   PubMed Web of Science ®Google Scholar
• Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000;283(10):1295–1302. doi:10.1001/jama.283.10.1295
   PubMed Web of Science ®Google Scholar
• Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293–302.
   PubMed Web of Science ®Google Scholar
• Rossello X, Ariti C, Pocock SJ, et al. Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials. Clin Res Cardiol. 2019;108(5):477–486. doi:10.1007/s00392-018-1378-0
   Web of Science ®Google Scholar
• Wikstrand J, Wedel H, Castagno D, McMurray JJ. The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF. J Intern Med. 2014;275(2):134–143. doi:10.1111/joim.12141
   Web of Science ®Google Scholar
• MERIT-HF. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353(9169):2001–2007. doi:10.1016/S0140-6736(99)04440-2
   Web of Science ®Google Scholar
• CIBIS-II. The cardiac insufficiency Bisoprolol study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9–13. doi:10.1016/S0140-6736(98)11181-9
   Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–717. doi:10.1056/NEJM199909023411001
   PubMed Web of Science ®Google Scholar
• Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21. doi:10.1056/NEJMoa1009492
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. doi:10.1056/NEJMoa1611925
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306. doi:10.1056/NEJMoa1811744
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357. doi:10.1056/NEJMoa1812389
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. doi:10.1056/NEJMoa1504720
   PubMed Web of Science ®Google Scholar